Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

USANA files lawsuit

This article was originally published in The Tan Sheet

Executive Summary

USANA Health Sciences announces March 15 it has filed a lawsuit against the Fraud Discovery Institute and Barry Minkow in the U.S. District Court in Salt Lake City, Utah for defamation. In a March 15, 2007 Wall Street Journal article Minkow said he bought "put" options on USANA's shares in a bet the price will fall. The Salt Lake City-based firm says in a release it believes "this is a campaign to manipulate USANA's stock price that is being orchestrated by an individual who served 7 years in prison for stock fraud." The company says Minkow's assertions about USANA's sales model are "false and misleading." In January the firm said it expected net sales for its fourth quarter to be approximately $101 mil. before it reclassified its financial report (1"The Tan Sheet," Jan. 15, 2007, In Brief)...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS100322

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel